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Change of the EGFR expression and downstream signal pathway 
in A549 cell Treated with ZD1839
Xu, Chongrui; Guo, Ailin; Lin, Jiayin; Zhou, Qing; Wang, Zheng; 
Wang, Kun; Yang, Suqing; Wu, Yilong 
Guangdong Provincial People’s Hospital, Guangzhou, China
Object: Discuss the change of the EGFR expression and downstream 
signal pathway in A549 cell treated with ZD1839. 
Methods: The inhibition of the A549 cell treated with ZD1839 was 
measured by MTT assay and Real-Time PCR was used to evaluate the 
expression of EGFR and downstream signal pathway. 
Results: A549 cell was inhibited by ZD1839 in vitro. After treated 
with ZD1839, the expression of EGFR was 1.10 fold compared with 
the cell without ZD1839 and Ras gene was 1.09 fold. The expression 
of MAPK was 52.1 percent of the cell without ZD1839, PI3K was 16.4 
percent and Akt was 25.3 percent. ZD1839 didn’t affect the expression 
of EGFR and Ras in A549 cell but down regulated the expression of 
MAPK, PI3k and Akt. 
Conclusion: ZD1839 inhibited A549 cell by inhibiting the tyrosine 
kinase activity of EGFR and the PI3K/Akt, MAPK signal pathway.
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Expression and significance of RUNX3 in human lung cancer
Yanada, Masashi1 Shimada, Junichi1 Ito, Kazuhiro1 Terauchi, Kunihiko1 
Shimomura, Masanori1 Yaoi, Takeshi2 Fushiki, Shinji2 
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University of Medicine, Kyoto, Japan 2 Dept. of Pathology and Applied 
Neurobiology, Kyoto Prefectural University of Medicine, Kyoto, Japan 
Background: Lung cancer is the leading cause of cancer related 
deaths throughout the world. A better understanding of the molecular 
pathogeneses of lung cancers is needed in order to achieve a preven-
tive or therapeutic breakthrough for reducing the number of deaths. 
Runt-related transcription factor 3 (RUNX3) has recently been shown 
to be down-regulated in human cancer tissues, including lung cancer. 
However, the clinical value of that ﬁnding is largely unknown. We in-
vestigated the associations of RUNX3 expression in lung cancer tissues 
with clinical characteristics and tumor recurrence.
Materials and Methods: The expression of RUNX3 in lung cancer 
cell lines was examined using a quantitative real-time reverse transcrip-
tase-polymerase chain reaction (RT-PCR) method. We also determined 
whether the expression of RUNX3 in the cell lines was associated with 
hemizygous deletion of the locus and methylation status in the exon 
1. Further, we investigated the methylation status of RUNX3 using a 
methylation speciﬁc PCR (MSP) technique and studied hemizygous 
deletion using bicolor ﬂuorescence in situ hybridization (FISH). In 
addition, primary lung tissues were obtained from Kyoto Prefectural 
University of Medicine, Japan. Among the 56 cases conﬁrmed as pri-
mary lung carcinomas, 40 were adenocarcinomas, 15 were squamous 
cell carcinomas, and 1 case was large cell carcinoma. The intratumoral 
expression level of RUNX3 mRNA was determined and compared with 
that in adjacent non-tumorous lung tissue using quantitative real-time 
RT-PCR in the 56 cases of non-small cell lung cancer. From those 
results, the relationship between the expression level of RUNX3 and 
clinicopathological factors was examined.
Results: RUNX3 gene expression was reduced or disappeared in all 
cell lines examined (P < 0.001). Eight of 15 lung cancer cell lines 
revealed methylated bands of RUNX3, whereas 7 showed unmethyl-
ated bands. Further, hemizygous deletion of RUNX3 was observed in 
8 of the cell lines by bicolor FISH. RUNX3/GAPDH mRNA levels 
were signiﬁcantly different between tumor tissues from the lung cancer 
specimens and adjacent non-malignant lung tissues (P < 0.001). No 
signiﬁcant differences in RUNX3/GAPDH mRNA levels were found 
related to age, gender, lymph node metastasis or tumor recurrence in 
the non-small cell lung cancer cases.
Conclusions: The present clinical and experimental data suggest 
that the comprehensive study of RUNX3 using quantitative real-time 
RT-PCR, MSP, and FISH would be beneﬁcial for understanding the 
pathogenetic mechanisms of human lung cancer at the molecular level.
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Growth regulation via insulin-like growth factor binding protein-4 
and -2 in lung epithelial cells and cancers
Yazawa, Takuya1 Sato, Hanako2 Shimoyamada, Hiroaki1 Okudela, Koji1 
Kitamura, Hitoshi1 
1 Dept. of Pathobiology, Yokohama City University Graduate School of 
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Gain-of-function point mutation in K-ras affect early events in pulmo-
nary bronchioloalveolar carcinoma and continuous K-Ras activation 
accelerates growth of lung epithelial cells. We investigated altered 
mRNA expression on K-Ras activation in human lung epithelial cells 
and found that two kinds of growth-modulating molecules, insulin-
like growth factor binding protein (IGFBP)-4 and -2 was signiﬁcantly 
upregulated by mutated K-ras transgene. Lung cancer cell growth was 
also accelerated by mutated K-ras gene transduction, whereas IGFBP-
4/-2 induction was weaker compared with mutated K-Ras-expressing 
lung epithelial cells. To understand the differences in IGFBP-4/-2 
inducibility via K-Ras-activated signaling between nonneoplastic 
lung epithelia and lung carcinoma, we addressed the mechanisms of 
IGFBP-4/-2 transcriptional activation. Our results revealed that Egr-1, 
which is induced on activation of Ras-MAPK signaling, is crucial for 
transactivation of IGFBP-4/-2. Furthermore, IGFBP-4 and IGFBP-2 
promoters were often hypermethylated in lung carcinoma, yielding low 
basal expression/weak induction of IGFBP-4/-2. These ﬁndings suggest 
that continuous K-Ras activation accelerates cell growth and evokes 
a feedback system through IGFBP-4/-2 to prevent excessive growth. 
Moreover, this growth regulation is disrupted in lung cancers because 
of promoter hypermethylation of IGFBP-4/-2 genes.
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Identification of novel tumor suppressor gene candidates in small 
cell lung cancer for use in cancer gene therapy
Zandi, Roza1 Willumsen, Berthe M.2 Pedersen, Nina1 Poulsen, Hans S.1 
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University Hospital, Copenhagen, Denmark 2 Department of Molecular 
Biology, University of Copenhagen, Copenhagen, Denmark 
Small cell lung cancer (SCLC) is a deadly disease with no current 
satisfactory treatments. There is thus an urgent need for development of 
more efﬁcient treatment modalities for patients with this cancer form. 
One intriguing modality is cancer gene therapy and one the most com-
mon approaches is tumor suppressor restoration therapy. In tumor sup-
pressor restoration therapy a wild-type tumor suppressor gene (TSG) is 
